Intensive insulin therapy

ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING

Retrieved on: 
Thursday, April 28, 2022
AREC, Diabetes, Injection, Blood, Type 2 diabetes, Patient, AIM, Gold, Research, Intensive insulin therapy, Medical school, Joanneum Research, ATTD, Insulin, Absorption, Population, Pharmaceutical industry

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing todays therapies to enable healthier lives, today presents positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the 15th International Advanced Technologies and Treatments for Diabetes (ATTD) meeting.

Key Points: 
  • Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing todays therapies to enable healthier lives, today presents positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the 15th International Advanced Technologies and Treatments for Diabetes (ATTD) meeting.
  • Dr Eva Svehlikova, Investigator for the ARE-278-102 study, said: Currently, there are no concentrated (>200U/mL) rapid acting insulin products on the market.
  • These results are clinically significant and suggest that AT278 has the potential to be the first ultra-concentrated, ultra-rapid insulin available to diabetic patients.
  • Sarah Howell, Chief Executive Officer of Arecor, added: Presenting the positive data achieved in our successful AT278 Phase I clinical study at ATTD marks another significant step forward for Arecors best-in-class diabetes franchise.

Global Continuous Glucose Monitoring Market to 2025: Business Moving Faster than Previously Anticipated - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Diabetes, Health, Medical Devices, Intensive insulin therapy, Eye, Patient, Insurance, Pharmacy, Glucose meter, Diabetes, CGM, Chief executive officer, Death, API, Research, Social media, Marketing, CE, IIT, GlySens ICGM, Smartphone, Industry, FDA, Software, CGMS-A, Medical device

The "Continuous Glucose Monitoring (CGM) Market Scope and Opportunities 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring (CGM) Market Scope and Opportunities 2025" report has been added to ResearchAndMarkets.com's offering.
  • The CGM business is moving faster than anticipated a few years ago.
  • There are faster approvals by the U.S. FDA and CE marks and regulatory authorities from other parts of the world.
  • There will be an expansion in the market in terms of targeting Type 1 patients and Type 2 patients with Intensive Insulin Therapy (IIT).

BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health

Retrieved on: 
Monday, September 27, 2021
Technology, Mobile, Wireless, Medical Devices, Diabetes, Other Technology, Clinical Trials, Software, Biotechnology, Health, Therapy, ALCOR, Partnership, Compliance, Digital health, Solution, Sale, Patient, Novo Nordisk, Diabetes, CEO, Introduction, Disease, Technology, SMED, Insulin, Intensive insulin therapy, Time, Pharmaceutical industry

Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins.

Key Points: 
  • Most Novo Nordisk's insulins are offered with the FlexTouch pen, and it is part of the launch map for all new insulins.
  • Upon successful development, Novo Nordisk plans to distribute the smart device in selected countries, and Biocorp expects to ramp up production volumes from 2022.
  • Novo Nordisk collaborates with Biocorp as we believe people with diabetes deserve the freedom to decide which solution works best for them.
  • Biocorp is very proud to sign this partnership with the world's leading diabetes company, Novo Nordisk, and it is a huge recognition for our Mallya.

$11.4 Billion Global Rapid Acting Insulin Market (2021 to 2027) - Industry Analysis Report and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021
Health, Pharmaceutical, Branches of biology, Clinical medicine, Endocrine system, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Intensive insulin therapy, ATC code A10

A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.

Key Points: 
  • A rapid-acting insulin is considered as an insulin analog created to mimic meal-induced insulin secretion.
  • By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible.
  • Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine.
  • There is a growing case of diabetes and an increasing geriatric population, which is boosting the regional rapid-acting insulin market.

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

Retrieved on: 
Friday, June 11, 2021
Diabetes, Medical devices, Health, Other Technology, Technology, Medicine, Clinical medicine, Diabetes, Medical monitoring, Blood glucose monitoring, Dexcom, Diabetes management, Continuous glucose monitor, Intensive insulin therapy, Insulin, Type 1 diabetes, Insulin pump

View the full release here: https://www.businesswire.com/news/home/20210611005428/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210611005428/en/
    The Dexcom G6 CGM System now covered by BC PharmaCare for people living with diabetes who are on intensive insulin therapy.
  • Diabetes.
  • Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial.
  • Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021
Clinical medicine, Medicine, Endocrinology, Diabetes, Insulin pump, Peptide hormones, Recombinant proteins, Insulin, Bolus, Intensive insulin therapy, Untethered regimen

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021
Clinical medicine, Medicine, Endocrinology, Diabetes, Insulin pump, Peptide hormones, Recombinant proteins, Insulin, Bolus, Intensive insulin therapy, Untethered regimen

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Glooko, Injector pen, Diabetes management software, Intensive insulin therapy

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Medicine, Organ systems, Diabetes, Insulin, Carbohydrate counting, Blood glucose monitoring, Type 1 diabetes, Injector pen, Intensive insulin therapy, Insulin pump

This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.

Key Points: 
  • This integration will follow the recent launch of the Novo Nordisk smart insulin pen data integration into the mySugr app.\n"Having diabetes is often described as a full-time job.
  • The time spent on activities that come with insulin therapy blood glucose monitoring, carbohydrate counting, injections, and lifestyle planning can add up to several hours a week," said Marcel Gmuender, Global Head of Roche Diabetes Care.
  • The Tempo Smart Button will attach to Lilly\'s Tempo Pen, a modified version of Lilly\'s existing prefilled, disposable insulin pen.
  • "We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Diabetes, Organ systems, Medicine, Diabetes management, Insulin, Type 2 diabetes, Type 1 diabetes, Hypoglycemia, Injector pen, Intensive insulin therapy, Book:Diabetes mellitus type 1

"Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.

Key Points: 
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • These solutions may also help address psychological barriers like fear of hypoglycemia that may negatively impact diabetes management.
  • Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases2.
  • These agreements and the Tempo Pen and Tempo Smart Button are part of Lilly\'s current and contemplated connected diabetes solutions and reflect Lilly\'s current beliefs and expectations.